Project: BUPI – a long-acting lozenge with bupivacaine for pain relief of Oral Mucositis in cancer patients

Moberg Pharma and partners will further develop and commersialise BUPI - an innovative and superior long-acting treatment for cancer patients suffering from pain associated with Oral Mucositis (OM). BUPI will be evaluated in a phase III trial. The project will deliver a final product ready for registration and thereafter launch – with documented benefits for patients.

Acronym	BUPI (Reference Number: 9794)
Duration	01/10/2015 - 01/10/2018
Project Topic	Biological Sciences / Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 3

Project partner

Number	Name	Role	Country
21772	Moberg Pharma AB	Coordinator	Sweden
21773	Oracain ApS	Partner	Denmark
21774	PCG Clinical Services AB	Partner	Sweden
21775	TFS Trial Form Support ApS	Partner	Denmark
21776	Department of Oncology Skåne University Hospital Lund Sweden	Partner	Sweden
21777	Aarhus University Hospital, Department of Oncology	Partner	Denmark
21778	Department of Oncology and Radiotherapy, University Hospital Herlev	Partner	Denmark